These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 33851275)

  • 1. Development of an In Vivo Predictive Dissolution Methodology of Topiroxostat Immediate-Release Tablet Using In Silico Simulation.
    Li G; Yang H; Liu W; Shen C; Ji Y; Sun Y; Huo Q; Liu Y; Wang G
    AAPS PharmSciTech; 2021 Apr; 22(3):132. PubMed ID: 33851275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of in-vivo pharmacokinetic profile for immediate and modified release oral dosage forms of furosemide using an in-vitro-in-silico-in-vivo approach.
    Otsuka K; Wagner C; Selen A; Dressman J
    J Pharm Pharmacol; 2015 May; 67(5):651-65. PubMed ID: 25644429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model.
    Luo Z; Yu G; Han X; Yang T; Ji Y; Huang H; Wang G; Liu Y; Sun W
    Biomed Pharmacother; 2020 Jan; 121():109660. PubMed ID: 31733581
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a Physiologically Relevant Population Pharmacokinetic in Vitro-in Vivo Correlation Approach for Designing Extended-Release Oral Dosage Formulation.
    Kim TH; Shin S; Bulitta JB; Youn YS; Yoo SD; Shin BS
    Mol Pharm; 2017 Jan; 14(1):53-65. PubMed ID: 27809538
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanistic investigation of the negative food effect of modified release zolpidem.
    Andreas CJ; Pepin X; Markopoulos C; Vertzoni M; Reppas C; Dressman JB
    Eur J Pharm Sci; 2017 May; 102():284-298. PubMed ID: 28286289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterising Drug Release from Immediate-Release Formulations of a Poorly Soluble Compound, Basmisanil, Through Absorption Modelling and Dissolution Testing.
    Stillhart C; Parrott NJ; Lindenberg M; Chalus P; Bentley D; Szepes A
    AAPS J; 2017 May; 19(3):827-836. PubMed ID: 28236228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of food effect on the oral absorption of clarithromycin from immediate release tablet using physiological modelling.
    Radwan A; Jayyousi R; Shraim N; Zaid AN
    Biopharm Drug Dispos; 2019 Apr; 40(3-4):121-134. PubMed ID: 30891805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets.
    Kocic I; Homsek I; Dacevic M; Grbic S; Parojcic J; Vucicevic K; Prostran M; Miljkovic B
    Biopharm Drug Dispos; 2012 Apr; 33(3):146-59. PubMed ID: 22374714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro-in vivo correlation of efavirenz tablets using GastroPlus®.
    Honório Tda S; Pinto EC; Rocha HV; Esteves VS; dos Santos TC; Castro HC; Rodrigues CR; de Sousa VP; Cabral LM
    AAPS PharmSciTech; 2013 Sep; 14(3):1244-54. PubMed ID: 23943401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro dissolution method fitted to in vivo absorption profile of rivaroxaban immediate-release tablets applying in silico data.
    Wingert NR; Dos Santos NO; Campanharo SC; Simon ES; Volpato NM; Steppe M
    Drug Dev Ind Pharm; 2018 May; 44(5):723-728. PubMed ID: 29192518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of absorption modeling to predict bioequivalence outcome of two batches of etoricoxib tablets.
    Mitra A; Kesisoglou F; Dogterom P
    AAPS PharmSciTech; 2015 Feb; 16(1):76-84. PubMed ID: 25182387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Justification of disintegration testing beyond current FDA criteria using in vitro and in silico models.
    Uebbing L; Klumpp L; Webster GK; Löbenberg R
    Drug Des Devel Ther; 2017; 11():1163-1174. PubMed ID: 28442890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine.
    Jantratid E; Prakongpan S; Amidon GL; Dressman JB
    Clin Pharmacokinet; 2006; 45(4):385-99. PubMed ID: 16584285
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro dissolution models for the prediction of in vivo performance of an oral mesoporous silica formulation.
    McCarthy CA; Faisal W; O'Shea JP; Murphy C; Ahern RJ; Ryan KB; Griffin BT; Crean AM
    J Control Release; 2017 Mar; 250():86-95. PubMed ID: 28132935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Understanding the in vivo performance of enteric coated tablets using an in vitro-in silico-in vivo approach: case example diclofenac.
    Kambayashi A; Blume H; Dressman J
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1337-47. PubMed ID: 24056057
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Silva TMD; Honorio TDS; Chaves MHDC; Duque MD; Cabral LM; Patricio BFC; Rocha HVA
    Drug Dev Ind Pharm; 2021 Aug; 47(8):1342-1352. PubMed ID: 34622730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans.
    Shono Y; Jantratid E; Kesisoglou F; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2010 Sep; 76(1):95-104. PubMed ID: 20576487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
    Chakraborty S; Yadav L; Aggarwal D
    Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of a Population Pharmacokinetics-Based in vitro-in vivo Correlation Model for Drugs with Site-Dependent Absorption: the Acyclovir Case Study.
    Shin S; Kim TH; Lee DY; Chung SE; Lee JB; Kim DH; Shin BS
    AAPS J; 2020 Jan; 22(2):27. PubMed ID: 31938935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.